Floatz logo

Tarlatamab

Merkel Cell Carcinoma

University of Arizonamonoclonal_antibodyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

45 Active assets in the Merkel Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 2/3BB
Durvalumab
Ariceum Therapeutics GmbH
Phase 2B
Atezolizumab
Ariceum Therapeutics GmbH
Phase 2B
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Tarlatamab is also rated in:

small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
medullary thyroid gland carcinomaDormant
B
Indicative ·
60 / 100
View asset →
neuroendocrine carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →